In close collaboration with fellow scientists, ACliRA Consulting ApS participated in the publication of an important Phase 1 study for the compound Zapnometinib, a MEK-inhibitor with excellent immunmodulating properties in development for the treatment of viral respiratory infections. The company conducting the study was ATRIVA Therapeutics GmbH in Tübingen/Germany, a very longstanding and close client of ACliRA. We are very proud of this achievement and want to express our warmest thanks to all partners involved in this study, especially to Prof. Oliver Planz from Tübingen University, who was the lead author for this publication.
You can download and read the publication here free of charge:
https://www.frontiersin.org/articles/10.3389/fphar.2026.1743230
